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Cytotoxic chemotherapy in advanced
non-small cell lung cancer
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Lung cancer is still the leading cause of can-
cer-related deaths in Western countries [1]. In the
past decade incidence rates showed a decreasing
trend in men, while is on the rise in women. The 5-
year survival rate in the 1990s was 14%, which
represents a minimal increase from the historical
13% of the 1970s. Around 80% of cases are Non-
Small Cell Lung Cancer (NSCLC) and most of pa-
tients present with either locally advanced (stage
III) or metastatic disease (stage IV).
The cure rate for radically resected patients
does not exceed 70% in stage I disease, thus creat-
ing the issue of occult micro-metastatic disease at
diagnosis. Therefore almost all patients will need
at some point of their clinical history a systemic
treatment to control the spread of the disease. In
advanced NSCLC chemotherapy remains the cor-
nerstone of treatment. A crucial step is whether the
impact of chemotherapy in the management of this
disease justifies either the toxicity and the ever in-
creasing costs. Differing points of view are still
quite common among medical and radiation on-
cologists, respiratory physicians and thoracic sur-
geons, which may ultimately lead to different clin-
ical approaches.
Historically, chemotherapy in advanced stages
has been viewed as palliative [2]. A survey from
the U.S. showed how less than one-third of pul-
munologists had some belief in the curative effect
of chemotherapy in advanced NSCLC [3]. In the
past only one-fifth of patients with metastatic lung
cancer routinely received any form of treatment
outside clinical trials. No clear advantage from
agents in use at the time was evident, with re-
sponse rates of less than 20% with single-agent
cisplatin, mitomycin, ifosfamide, etoposide, and
the vinca alkaloids vinblastine and vindesine; re-
sults were slightly higher for combination regi-
mens but without any significant impact on long-
term survival.
However a number of randomised trials
demonstrated an improved 1-year survival rate for
patients treated with chemotherapy when com-
pared with BSC. This data was then grouped into a
meta-analysis [4]: 11 trials examined BSC versus
chemotherapy plus BSC (8 out of 11 trials used
cisplatin-based regimens) in stage III and IV
NSCLC. Patients treated with cisplatin-containing
regimens demonstrated a 27% reduction in the risk
of death, which translated into an absolute im-
provement in survival of 10% at 1 year with a
modest but significant gain in median survival of
1.5 months. Further analysis did not demonstrate
that any subgroup based on sex, age, histology,
performance status, or stage could benefit more or
less than others. Evidence that patients who re-
ceived cisplatin-based chemotherapy in addition to
surgery or radiotherapy also had improved out-
comes strongly supported the idea that cisplatin
plays a major role in combined modality treatment
of NSCLC. The majority of combinations consist-
ed of cisplatin plus either a vinca alkaloid or
etoposide: although results were modest, they
were nonetheless important from a public health
perspective, given the large numbers of patients
with NSCLC who could potentially receive bene-
fits from such treatment.
The optimistic view is further supported by
one of the first prospective studies designed to
measure the impact of chemotherapy on quality of
life that showed an improvement of tumor-related
symptoms in 69% of patients: efficacy was highest
in the first 2 courses thus showing an early pallia-
tion [5]. Two further randomised studies con-
firmed how quality of life, as measured through
specific questionnaires, definitely improved in the
chemotherapy arm  [6, 7]. Moreover with an eye
toward health economics, chemotherapy proved
superior over BSC in terms of cost-effectiveness
due to a reduced number of days of hospitalisation
as a result of a better control of cancer-related
symptoms [8]. This data could also be reproduced
by analysing costs from other studies employing
cisplatin-based combinations with either vinorel-
bine or gemcitabine [9, 10, 11].
In the 1990s new agents with novel mecha-
nisms of action and a proven activity in NSCLC
were introduced into common clinical practice.
Such agents include the taxanes (paclitaxel and do-
cetaxel), a new vinca alkaloid (vinorelbine), a nov-
el deoxycytidine analog (gemcitabine) and the
topoisomerase I inhibitors (irinotecan and topote-
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can). Optimistic oncologists showed precocious
enthusiasm for the efficacy and good toxicity pro-
file as single-agents or in combination with a plat-
inum compounds; as single-agent they produced
response rates which exceeded 20% [12] and 50%
or greater when combined with cisplatin or carbo-
platin.
When these newer agents plus a platinum ana-
log were tested against standard regimens in use at
that time platinum-based doublets containing new
agents showed improvements in survival in few
cases and in most clinical trials proved to be of
equivalent efficacy with a better toxicity profile.
Two European studies compared cisplatin/
gemcitabine with either cisplatin/etoposide [13] or
mitomycin/ifosfamide/cisplatin (MIC) [14]. Re-
sponse rates were higher for the gemcitabine/cis-
platin regimen: 40% and 38% compared to 22%
for etoposide/cisplatin and 26% for MIC. No dif-
ferences were noted in 1-year and median survival
rates, while in the Spanish study a statistically sig-
nificant advantage in time to progression was
achieved in the gemcitabine arm (6.9 vs 4.3
months).
In this issue Berghmans et al. demonstrated
how MIC combination is retaining its activity in an
off-protocol setting and the participation in a clini-
cal trail is not ending up in a better survival. This in-
formation is reinforcing MIC as a reasonable thera-
peutic strategy in our daily clinical practice [15].
Results are however conflicting. An optimist
could see an evident improvement in response
rates (even though not always statistically signifi-
cant) with newer combinations, which proved to
be at least as effective as older ones, with an
equivalent if not better toxicity profile and an
overall improvement of quality of life. In almost
all cases the combination with a platinum deriva-
tive is superior to single-agent cisplatin. The nega-
tive view can stress the limited survival advantage
gained at the expense of sometimes higher toxici-
ty (although usually manageable) and of defini-
tively higher costs compared to older drugs of the
1980s. Moreover, historical comparisons with old-
er regimens are difficult due to stage and prognos-
tic factors migration.
However, the superiority of any newer regi-
men in terms of improved survival, quality of life,
and toxicity profile remains unclear. The more
commonly used platinum-based doublets includ-
ing a newer agent were compared “face to face” in
four randomised clinical studies. All these studies
have failed to demonstrate the superiority of any
one of these so-called third-generation regimens
over the others in terms of improved tumour re-
sponse rates or survival rates, although the regi-
mens do have different toxicity profiles [16].
Given the similarity in the effectiveness of
combination regimens, decisions regarding treat-
ment for advanced NSCLC should take into ac-
count the toxicity profiles, convenience and costs.
Healthcare utilisation data is beginning to be col-
lected prospectively during clinical trials of
chemotherapeutic regimens so that economic
analyses can be performed.
In conclusion, in advanced non-small cell lung
cancer efficacy outcomes of phase III studies of
third generation agents plus platinum compounds
point in the direction of an “efficacy plateau”.
Molecular targeted therapies and pharmacogenom-
ic represent reliable platforms for the next genera-
tion of clinical trials.
Preclinical research has now made available an
array of keys to explain the biologic mechanisms
involved in cellular replication and signaling path-
ways. Novel agents able to target specific steps of
the neoplastic transformation and uncontrolled
proliferation have already entered the clinical
phases and most of them have already failed, alone
or in combination with cytotoxic chemotherapy.
At the different levels of the signaling pathways
receptor-associated tyrosine kinase inhibitors, a
variety of monoclonal antibodies directed against a
variety of growth factors and specific inhibitors
have been more or less extensively investigated
with conflicting results. Although some of these
targeted agents have already demonstrated cyto-
toxic activity in the setting of second- and third
line therapy of advanced non-small cell lung can-
cer, when combined with doublets in the first line
setting, they have produced disappointing results.
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